• Assessing whether RhoC expression in prostate cancers can be used to predict the likelihood of metastic spread (funded by a grant from the Prostate Cancer Foundation of Australia - PCFA)
  
• Development and validation of immunohistochemical markers for prediction of outcomes following radical prostatectomy, and for predicting the need for surgery following needle biopsy (Collaborators: Cancer Council Victoria; Royal Melbourne Hospital; Alfred Hospital)
• Correlation between MRI imaging of prostate cancer in vivo and actual tumour mass and localization following radical prostatectomy (Collaborator: Mercy Hospital Private Radiology, Melbourne)
• Relationship between prostate cancer and stem cells (Collaborator: Monash Institute for Medical Research)
• Role of inhibins in development of prostate cancer (Collaborator: Monash Institute for Medical Research)
• Anatomy of the seminal vesicles (Collaborator: Royal Melbourne Hospital)
• Using morphological and protein expression markers to subdivide prostate cancers of Gleason pattern 3 (Collaborator: Monash Institute for Medical Research)
• Can expression of apoptosis markers assist in diagnosis of prostate cancer? (Collaborator: Peptech and Biosceptre Corporation, Sydney).
• 
  

TissuPath is actively involved in "tissue banking" (freezing leftover pathology specimens for use in future research, with approval of the patient) and is the only private pathology laboratory that is an Affiliate Member of the recently-funded Victorian Cancer BioBank as well as a Founding Member of the Victorian Prostate Cancer Research Consortium.